Boston Scientific: Study to boost implantable cardiac devices market

07/21/2009 | Boston Globe (tiered subscription model), The

Boston Scientific believes that its MADIT-CRT study, which is aimed at testing the efficacy of cardiac resynchronization therapy in slowing the progression of early-stage heart failure, could expand the market for implantable heart devices. The company plans to ask the FDA to get expanded label indication for CRT defibrillators by the end of the year and hopes to secure approval by mid-2010, CEO Ray Elliott said.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN